Histone Deacetylase Inhibitors as Anticancer Drugs
Open accessThe DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.
Abstract
Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response. Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc. HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy. HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma. Other HDAC inhibitors are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising but further larger studies are needed. Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance. Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclinical and clinical studies, including the combination with other therapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HDAC inhibitors have been considered for usage in combinatorial therapies for several cancers including melanoma47,65–67.”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work as anticancer drugs by inducing cell cycle arrest, differentiation, and cell death, and by reducing angiogenesis and modulating the immune response; however, the mechanisms of their effects can differ depending on the individual HDAC inhibitor and its dose and on the type of cancer [164].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [164]
In the citing paper
“HDAC inhibitors act as antitumoral agents by antagonizing the pro-transcriptional effects of histone deacetylation and silencing the expression of oncogenic factors through chromatin remodeling43.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R. I., Friedberg, J., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 105 · cited 2×
“SAHA carfilzomib in vitro and nude mice xenografts, lymphoma cell SUDHL16, SUDHL4 , SUDHL6, OCI-LY10, OCI-LY3 bortezomib-resistant SUDHL16-10BR, OCI-LY10-40BR and lymphoma cells frompatients Potentiation [152]”
BackgroundRetractedDasmahapatra, G., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 57 · cited 2×
“SNDX-275, SAHA carfilzomib, bortezomib in vitro and nude mice xenografts, lymphoma cell Granta 519, Rec-1, HF-4B, JVM-2, MINO, JVM-13 Potentiation [153]”
BackgroundRetractedBalliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31 · cited 3×
“Moreover, inhibition of HDAC6 activates naïve T cells [119,120].”
BackgroundRetractedThe Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325 · cited 1×
“The Wnt signaling pathway plays an important role in various cancers such as colon, breast, ovarian, prostate and endometrial cancers as well as medulloblastoma and melanoma [103].”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“Several tumor associated antigens have been shown to be epigenetically silenced in malignancies impede immune recognition by cytotoxic T cells and contributing to worse prognosis [124,125].”
BackgroundActivation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203 · cited 2×
“Therefore, HDACs may be essential for the maintenance of a set of key genes required for survival and growth of cancer cells but not of normal ones [38].”
BackgroundAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“HATs catalyze the transfer of an acetyl group from acetyl-CoA to the ε-NH2 group of lysine residues in proteins, while HDACs remove it [12].”
BackgroundRegulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608 · cited 1×
“eNOS, Akt in vitro endothelial cells, Akt transfected, mutatnteNOS / [110]”
Background
Cited by
Items 801–900 of 1,000
The roles of enhancer, especially super-enhancer-driven genes in tumor metabolism and immunity
Guo, S., Zhang, L., Ren, J., Lü, Z., Ma, X., Liu, X., Jin, H., & Li, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142414 · Cited by 7
Biersack, B. (2018) · Non-coding RNA Research · doi:10.1016/j.ncrna.2018.11.001 · Cited by 8
“the treatment of T cell lymphoma and multiple myeloma [198].”
BackgroundThe Landscape of Histone Modification in Cancer Metastasis
Qiu, Z., Wang, J., & Wu, Y. (2018) · IntechOpen eBooks · doi:10.5772/intechopen.78383 · Cited by 6
“Thus far three HDACi: vorinostat (SAHA), romidepsin (Istodax) and PTCL (Belinostat or Beleodaq) are approved by the FDA for some T-cell lymphomas [33].”
BackgroundLee, H., Park, S.-M., Chu, K., Quan, F., Kurz, T., Pflieger, M., & Moon, E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01506-20 · Cited by 7
Peters, G. J., van Gemert, F. P. A., Kathmann, I., Reddy, G., Cillessen, S. A. G. M., & Jansen, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.577215 · Cited by 6
“Belinostat (BLS) is a hydroxamic acid-based pan-histone deacetylase (HDAC) inhibitor that inhibits all of the zincdependent HDAC enzymes, with high affinity for the Class I, II and IV isozymes (Eckschlager et al., 2017).”
BackgroundInfluentialEffect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2
Lee, S., Wang, S., Yu, C.-L., Tai, H., Yen, J.-Y., Tuan, Y.-L., Wang, H.-H., Liu, Y.-T., Chen, S.-S., & Lee, H. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116454 · Cited by 8
Zolghadri, S., Ghanbariasad, A., Fallahian, F., Rahban, M., Kalavani, M., Jahromi, E. B., Asadzadeh, A., & Hajiani, M. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06881-1 · Cited by 6
Mitigation of radiation injury to reproductive system of male mice by Trichostatin A
Haritwal, T., Kalra, N., & Agrawala, P. K. (2022) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2022.503522 · Cited by 6
Dynamic monitoring of STAT3 activation in live cells using a novel STAT3 Phospho-BRET sensor.
Dimri, S., Arora, R., Jasani, A., & De, A. (2019) · Europe PMC (PubMed Central) · Cited by 10
Sirtuiny – enzymy o wielokierunkowej aktywności katalitycznej
Kratz, E. M., Sołkiewicz, K., Kaczmarek, A., & Piwowar, A. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0014.7866 · Cited by 7
Joglekar, M. V., Sahu, S., Wong, W. K. M., Satoor, S. N., Dong, C. X., Farr, R. J., Williams, M. D., Pandya, P., Jhala, G., Yang, S. N. Y., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.01.008 · Cited by 7
Harshitha, K., Nair, R. A., & Pillai, P. P. (2022) · Phytochemistry Letters · doi:10.1016/j.phytol.2022.12.003 · Cited by 7
Fukumoto, T., Zhang, R., & Bitler, B. G. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1503050 · Cited by 6
Aging and tumors: a dynamic interaction
Zhang, Y., Zhu, S., Liu, Z., Hu, Y., Zhang, Y., Shang, L., & Li, L. (2025) · Discover Oncology · doi:10.1007/s12672-025-01808-9 · Cited by 5
“It exerts antitumor effects through mechanisms such as regulating gene expression, inducing apoptosis, arresting the cell cycle, inhibiting angiogenesis, and reducing immune evasion [86].”
Tubulin Acetylation: A Critical Regulator of Microtubule Function
Delgado, I. L. S., Carmona, B., Nolasco, S., Marques, R., Gonçalves, J., & Soares, H. (2025) · Results and problems in cell differentiation · doi:10.1007/978-3-031-91459-1_4 · Cited by 6
Targeting autophagy in dysfunctional tumor vasculature
Lin, Q., Cai, B., Ke, R., Ni, X., Wan, X., Chen, L., Huang, T., Shan, X., & Wang, B. (2025) · iScience · doi:10.1016/j.isci.2025.114084 · Cited by 6
“182 These epigenetic modifications are particularly dynamic in TECs due to their exposure to fluctuating oxygen levels and metabolic stress within the TME.”
Li, M., McGhee, E. M., Shinno, L., Lee, K., & Lin, Y. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.06.005 · Cited by 5
“Butyrate has received increasing attention because of its potential beneficial impact on gut epithelia and has been proposed as a potential treatment for a wide variety of conditions, from chronic inflammatory diseases to cancer.(61) In this study, MOKE6E7B showed enhanced resistance to environmental stress, reduced p…”
BackgroundYan, A., Zhao, Y., Zhang, L., Liang, X., Zhang, X., Liang, F., Nian, S., Li, X., Sun, Z., Li, K., et al. (2022) · Open Life Sciences · doi:10.1515/biol-2022-0095 · Cited by 5
“Class I HDACs, which include HDAC1, 2, 3, and 8, are the most abundant HDACs localized in the nucleus [40,41].”
BackgroundSolid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors
Bachmann, L. M., Hanl, M., Feller, F., Sinatra, L., Schöler, A., Pietzsch, J., Laube, M., & Hansen, F. K. (2023) · Molecules · doi:10.3390/molecules28031061 · Cited by 6
Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials?
Fanciulli, G., Modica, R., Salvia, A. L., Grossrubatscher, E. M., Florio, T., Ferraù, F., Veresani, A., Russo, F., Colao, A., & Faggiano, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1145926 · Cited by 5
“HDACinhibitors seem to be promising anti-cancer drugs particularly in the combination with other anticancer drugs (32).”
BackgroundMishra, S., Verma, E., Patil, S., Rajani, D. P., & Gajbhiye, A. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101253 · Cited by 6
Thymic Carcinoma: Unraveling Neuroendocrine Differentiation and Epithelial Cell Identity Loss
Yamada, Y., Iwane, K., Nakanishi, Y., & Haga, H. (2023) · Cancers · doi:10.3390/cancers16010115 · Cited by 8
“DNA methylation status may be associated with these newly discovered signatures of thymic carcinomas.”
BackgroundFujita, N., Bondoc, A., Simoes, S., Ishida, J., Taccone, M. S., Luck, A. J., Srikanthan, D., Siddaway, R., Levine, A., Sabha, N. S., et al. (2024) · Brain Tumor Pathology · doi:10.1007/s10014-024-00493-w · Cited by 5
“HDAC inhibitors can affect cell cycle arrest, apoptosis, autophagy, non-coding RNA, cell differentiation via extracellular signal-regulated kinase pathways, anti-angiogenesis, and immunomodulation [33].”
PXD101 inhibits malignant progression and radioresistance of glioblastoma by upregulating GADD45A
Hu, X., Zhou, P., Peng, X., Ouyang, Y., Li, D., Wu, X., & Yang, L. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05874-5 · Cited by 5
Synthesis and Evaluation of 9-epi-Koshidacin B as Selective Inhibitor of Histone Deacetylase 1
Ghosh, R., Biswas, S., Bagchi, A., & Chattopadhyay, S. K. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.4c00913 · Cited by 7
Cheng, Z., Cheng, Z., Zhang, Y., & Zhang, S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189242 · Cited by 7
Frassanito, P., Thomale, U. W., Obersnel, M., Romano, A., Leblond, P., Knerlich‐Lukoschus, F., Due‐Tønnessen, B. J., Thompson, D. N. P., Rocco, F. D., & the CPN Lyon 2024 Consensus Conference Group (2025) · Child s Nervous System · doi:10.1007/s00381-025-06799-0 · Cited by 6
“The acetylation state is regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs) [31].”
Takahashi, S., Yoshida, K., Paudel, D., Morikawa, T., Uehara, O., Harada, F., Ariwansa, D., Giri, S., Sato, J., Nagayasu, H., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02928-y · Cited by 6
“Epigenetic drugs are often administrated prior to chemotherapy; alternatively, epigenetic drugs and chemotherapy are used together to achieve synergistic effects and maximize treatment efficacy [36].”
Farooqi, H., Anjum, A., Abdin, M., & Tiwari, A. K. (2021) · Pharmacognosy Magazine · doi:10.4103/pm.pm_70_21 · Cited by 5
Genetic and Epigenetic Sexual Dimorphism of Brain Cells during Aging
Shirokova, O. M., Zaborskaya, O., Pchelin, P. V., Kozliaeva, E. V., Pershin, V. I., & Mukhina, I. V. (2023) · Brain Sciences · doi:10.3390/brainsci13020195 · Cited by 5
Lawal, T. O., Patel, S., & Mahady, G. B. (2023) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v13i7.1105 · Cited by 6
Li, J., Tian, T., Han, B., Yang, T., Guo, Y., Wu, J., Chen, Y., Yang, Q., & Xie, R. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i34.5038 · Cited by 6
“So far, SAHA has been found to induce the differentiation of malignant tumor cells and accelerate apoptosis in vitro and in vivo [14].”
Histone Acyl Code in Precision Oncology: Mechanistic Insights from Dietary and Metabolic Factors
Neja, S. A., Dashwood, W. M., Dashwood, R. H., & Rajendran, P. (2024) · Nutrients · doi:10.3390/nu16030396 · Cited by 7
“…B-12, selenium, and zinc, alongside dietary compounds such as sulforaphane, tea polyphenols, curcumin, and allyl sulfur compounds, are part of an expanding arsenal that influences epigenetic processes [210,211] by targeting enzymes involved in histone acylation, such as HATs and HDACs [164,212].”
BackgroundCell-active small molecule inhibitors validate the SNM1A DNA repair nuclease as a cancer target
Bielinski, M., Henderson, L. R., Yosaatmadja, Y., Swift, L. P., Baddock, H. T., Bowen, M. J., Brem, J., Jones, P. S., McElroy, S. P., Morrison, A. J., et al. (2024) · Chemical Science · doi:10.1039/d4sc00367e · Cited by 5
“Hydroxamic acids have been developed for clinical use as histone deacetylase inhibitors, 42 though such compounds also have potential to inhibit other human metallo-enzymes 43 and to act as non-selective metal ion chelators.”
Chan, J. M.-L., Chang, Y.-C., Chan, H., Chan, H., Chang, W.-C., Wang, L.-F., Tsai, T., Chen, Y.-J., & Huang, W.-C. (2024) · Molecular Medicine · doi:10.1186/s10020-024-00835-6 · Cited by 5
Lee, Y.-J., Kim, H., Kim, E. S., Park, S., Ryu, K., & Lee, E. G. (2019) · Process Biochemistry · doi:10.1016/j.procbio.2019.06.029 · Cited by 5
Effect of valproic acid on cisplatin-resistant ovarian cancer cell lines
Sheikhshabani, S. H., Amini‐Farsani, Z., Shamsara, M., Sajadpoor, Z., Sangtarash, M. H., & Teimori, H. (2019) · Journal of Shahrekord University of Medical Sciences · doi:10.34172/jsums.2019.07 · Cited by 5
“Recently, VPA has been widely studied for its anti-cancer effects in many cancers (9-11).”
Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer
Facciotto, C., Casado, J., Turunen, L., Leivonen, S., Tumiati, M., Rantanen, V., Kauppi, L., Lehtonen, R., Leppä, S., Wennerberg, K., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0781-3 · Cited by 6
“In particular, treatment of Su-Dhl-4 cells with entinostat led to upregulation of CDKN1A, an HDAC inhibitor mechanism previously suggested to induce cell cycle arrest [23].”
BackgroundResultInfluentialEpigenetic Approaches to the Treatment of Renal Cell Cancer
Hong, S. H., Lee, J., Jang, E. B., Park, S. Y., Moon, H. S., & Yoon, Y. E. (2020) · Journal of Urologic Oncology · doi:10.22465/kjuo.2020.18.2.78 · Cited by 5
“Although not all HDACi are cleared for RCCs therapy, many of them are FDA-approved for their therapeutic effects against many diseases.(100)”
BackgroundArai, S., Takeuchi, S., Fukuda, K., Tanimoto, A., Nishiyama, A., Konishi, H., Takagi, A., Takahashi, H., Ong, S. T., & Yano, S. (2020) · The Journal of Medical Investigation · doi:10.2152/jmi.67.343 · Cited by 6
“It was also reported that mechanisms of antitumor effect of HDAC inhibitors may be different and depend on HDAC inhibitors (32).”
BackgroundSanaei, M., & Kavoosi, F. (2021) · Gastroenterology and hepatology from bed to bench. · Cited by 5
Shyu, Y.-M., Liu, L. Y., & Chuang, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810029 · Cited by 5
“It shall be noted that ETO has already been shown to enhance cytotoxicity and apoptosis when combined with VPA in several cancers [7,12,13].”
BackgroundPrevention of anticancer therapy-induced neurotoxicity: Putting DNA damage in perspective
Brinkmann, V., & Fritz, G. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.04.009 · Cited by 5
Akiyama, T. E., Yoshimatsu, Y., Noguchi, R., Sin, Y., Osaki, J., Ono, T., Adachi, Y., Tsuchiya, R., Toda, Y., Ogura, K., et al. (2023) · Human Cell · doi:10.1007/s13577-023-00932-4 · Cited by 5
Untargeted LC-MS/MS Metabolomics Study of HO-AAVPA and VPA on Breast Cancer Cell Lines
Estrada-Pérez, A. R., García-Vázquez, J. B., Mendoza-Figueroa, H. L., Rosales‐Hernández, M. C., Fernández–Pomares, C., & Correa‐Basurto, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914543 · Cited by 5
“Resveratrol is considered a pan inhibitor of HDAC [56,57], which has major activity on isoforms 1, 10, 4, and 9 of HDAC [56], all inhibited by VPA as well, except for HDAC10, so this might explain the similarities found between HDACi and VPA and HO-AAVPA [7].”
BackgroundInfluentialPharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer
Garmpis, N., Damaskos, C., Garmpi, A., Valsami, S. I., & Dimitroulis, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00013-9 · Cited by 9
KRCC1: A potential therapeutic target in ovarian cancer
Dwivedi, S. K. D., Shameer, K., Dey, A., Mustafi, S. B., Xiong, X., Bhattacharya, U., Neizer‐Ashun, F., Rao, G., Wang, Y., Ivan, C., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201902259r · Cited by 6
Alshawli, A. S., Wurdak, H., Wood, I. C., & Ladbury, J. E. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1429 · Cited by 6
“Interestingly, transformed cells are more sensitive to HDACi than normal cells (Eckschlager et al., 2017; Li & Zhu, 2014).”
BackgroundPal, D., Sur, S., Roy, R., Mandal, S., & Panda, C. K. (2021) · Journal of Biosciences · doi:10.1007/s12038-021-00176-0 · Cited by 6
A Cell-Based Screen Identifies HDAC Inhibitors as Activators of RIG-I Signaling
Fraile‐Bethencourt, E., Foss, M. H., Nelson, D., Malhotra, S. V., & Anand, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.837610 · Cited by 5
“Although HDAC inhibitors and PLK1 inhibitors have been extensively studied, their proposed mechanism(s) of action have been tumor centric (Gutteridge et al., 2016; Eckschlager et al., 2017).”
BackgroundMane, R. R., & Kale, P. P. (2022) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2022-0114 · Cited by 5
Enhancing progestin therapy via HDAC inhibitors in endometrial cancer.
Li, Y., Zhou, W., Li, L., Li, J. W., Li, T., Huang, C., Lazaro-Camp, V. J., Kavlashvili, T., Zhang, Y., Reyes, H., et al. (2022) · PubMed · Cited by 11
Pannell, C. A. (1993) · Massey Research Online (Massey University) · Cited by 5
Signalling pathways and cellular functions of KDEL receptors: implications in cancer biology
Dufrusine, B., Cela, I., Tota, C. G., Palumbo, M., & Sallese, M. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05820-8 · Cited by 5
“Inhibition of HDACs using HDAC inhibitors (HDACi) represents a promising therapeutic strategy for cancer treatment [ 55 ].”
Balakumar, P., Mulukuri, N. V. L. S., & Jagadeesh, G. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108945 · Cited by 7
Dudchak, R., Podolak, M., Bielawska, A., Bielawski, K., & Lesyk, R. (2026) · Molecules · doi:10.3390/molecules31091444 · Cited by 4
Parthiban, G., Dushanan, R., Weerasinghe, S., Dissanayake, D. P., & Senthilnithy, R. (2022) · Indonesian Journal of Chemistry · doi:10.22146/ijc.74167 · Cited by 4
“Targeted therapy, in contrast, focuses on cancer-specific targets and signaling pathways [3].”
BackgroundAvendaño, C., & Menéndez, J. C. (2023) · Medicinal Chemistry of Anticancer Drugs · doi:10.1016/b978-0-12-818549-0.00019-4 · Cited by 4
Histone epigenetic modifications and their relationship with cancer: a comparative medicine view
Senhorello, I. L. S., & Tinucci‐Costa, M. (2023) · Ciência Rural · doi:10.1590/0103-8478cr20220510 · Cited by 4
Inhibition of Heat Shock-Induced H3K9ac Reduction Sensitizes Cancer Cells to Hyperthermia
Lin, H., Song, Y., Song, L., Geng, Z., Cheng, R., Lei, Y., & Guo, F. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.86384 · Cited by 4
“such as vorinostat (SAHA) and panobinostat (LBH589) [22-24].”
BackgroundSenhorello, I. L. S., Matiz, O. R. S., Canavari, I. C., Hernandez, G. V., Anai, L. A., Ampuero, R. A. N., Pazzini, J. M., Prado, C. M., Meirelles, F. V., Vasconcelos, R. D. O., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1257932 · Cited by 5
Ahn, Y. R., Jang, J. Y., Kang, Y. J., Oh, H. J., Kang, M. K., Yoon, D., Kim, H. S., Moon, H. R., Chung, H. Y., & Kim, N. D. (2023) · Journal of Chemotherapy · doi:10.1080/1120009x.2023.2286757 · Cited by 4
“Newly developed HDAC inhibitors have recently come to the forefront as medications for combating cancer [11–13].”
Ammash, O. M., Alwan, S. M., Albakaa, A. R. M., & Sulaiman, İ. A. I. B. (2024) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v24i2.1059 · Cited by 4
Selective HDAC6 Inhibition Has the Potential for Anti-Cancer Effect in Renal Cell Carcinoma
Anraku, T., Murata, M., Kuroki, H., Kazama, A., Shirono, Y., Tasaki, M., Bilim, V. N., & Tomita, Y. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070704 · Cited by 4
“These HDAC inhibitors were initially shown to be effective for hematological malignancies rather than solid tumors [7].”
BackgroundGandupalli, L., Bhowmik, D., Jyotishi, C., & Gupta, R. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.313 · Cited by 5
“Several HDAC inhibitors also affect the activity of cytochrome P450 (CYP) enzymes, potentially enhancing the effects of certain anticancer drugs in combination with HDAC inhibitors (45).”
Bashir, B., Sethi, P., Panda, S., Manikyam, H. K., Vishwas, S., Singh, S. K., Singh, K., Jain, D., Chaitanya, M., & Coutinho, H. D. M. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111743 · Cited by 5
Su, B., LIM, D. J., Qi, C., Zhang, Z., Wang, J., Zhang, F., Dong, C., & Feng, Z. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05649-8 · Cited by 4
Hosseini, S. A., Mirzaei, S. A., Kermani, S., & Yaghoobi, H. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09284-0 · Cited by 4
“Histone deacetylase (HDAC) inhibitors induce apoptosis in various tumor cells [3].”
Sun, B., Yuan, Z.-X., Wang, M.-J., Xu, L., Feng, J., & Chen, J.-J. (2024) · Discover Oncology · doi:10.1007/s12672-024-01160-4 · Cited by 5
“Many genes, including those involved in cell cycle inhibition, differentiation, and apoptosis, cannot be expressed normally [25, 26].”
BackgroundTargeting histones for degradation in cancer cells as a novel strategy in cancer treatment
Yin, Y., Zhu, Q., Jiang, T.-X., Fan, L., & Qiu, X. (2018) · Science China Life Sciences · doi:10.1007/s11427-018-9391-7 · Cited by 4
Kenny, R. G., & Marmion, C. J. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016452-00001 · Cited by 10
Plazibat, M., Bojanac, A. K., Perić, M. H., Gamulin, O., Rašić, M., Radonić, V., Škrabić, M., Krajačić, M., Krasić, J., Sinčić, N., et al. (2020) · FEBS Journal · doi:10.1111/febs.15248 · Cited by 4
Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk
Chavez, A., Quesenberry, C. P., Darbinian, J. A., & Asgari, M. M. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.04.007 · Cited by 4
Park, S., Jeon, J.-H., Park, J.-A., Choi, J.-K., & Lee, Y. (2020) · Cell Stress and Chaperones · doi:10.1007/s12192-020-01161-6 · Cited by 5
“Because both HDAC inhibitors and proteasome inhibitors have an anti-tumor activity, many studies are underway to develop these as an anti-cancer drug, and several inhibitors have been tested and underwent clinical trials (Bolden et al. 2006; Crawford et al. 2011b; Curran and McKeage 2009; Cusimano et al. 2010; Dokmano…”
BackgroundOrtore, G., Poli, G., Martinelli, A., Tuccinardi, T., Rizzolio, F., & Caligiuri, I. (2021) · Medicinal Chemistry · doi:10.2174/1573406417666210511001241 · Cited by 6
Reproductive disease epigenetics
Colón-Díaz, M., Jaramillo, A. J., Soto, E. Y., & Elosegui, P. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00027-x · Cited by 5
Targeting cancers and metabolic disorders: The prospects of combining HDAC8 inhibitor and activator
Yusif, M. M. (2022) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2022.100097 · Cited by 5
Kusmiyati, M., Rusdin, A., Trinovani, E., Prawira-Atmaja, M. I., Purkon, D. B., & Mulyo, G. P. E. (2022) · Journal of Advanced Pharmaceutical Technology amp Research · doi:10.4103/japtr.japtr_422_22 · Cited by 4
“Surgery is generally ineffective for cells that have undergone metastases, while chemotherapy has not given optimal results, because the action of drugs is not specific and is relatively expensive.[1,8]”
BackgroundAndré, A., Dias, J., Aguiar, S. I., Leonardo, A., Nogueira, S., Amaral, J. D., Fernandes, C., Gano, L., Correia, J. D. G., Cavaco, M. C., et al. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1236136 · Cited by 5
“Among the compounds targeting epigenetic regulators, histone deacetylase inhibitors (HDACis) have emerged as a promising new class of anticancer therapeutics (13).”
BackgroundNatural Products for Cancer Prevention and Therapy
Bishayee, A., & Yerer-Aycan, M. B. (2018) · MDPI eBooks · doi:10.3390/books978-3-03897-311-9 · Cited by 5
Kaur, K. K., Allahbadia, G., & Singh, M. (2023) · doi:10.54646/bijrdpm.001 · Cited by 6
Martínez‐Archundia, M., Colin-Astudillo, B., Gómez-Hernández, L., Abarca‐Rojano, E., & Correa‐Basurto, J. (2019) · Molecular Simulation · doi:10.1080/08927022.2019.1579326 · Cited by 4
“In this work, we propose a novel strategy of designing SCFAs (known HDAC inhibitors, [17])”
BackgroundMethodDeacetylation mechanism of histone deacetylase 8: insights from QM/MM MP2 calculations
Lai, R., & Li, H. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp00002e · Cited by 4
López‐Corrales, M., Izquierdo‐García, E., Bosch, M., Das, T., Llebaria, A., Josa‐Culleré, L., & Marchán, V. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00550 · Cited by 3
Gopinathan, A., Sankhe, R., Upadhya, R., Pai, K. S. R., & Kishore, A. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05341-9 · Cited by 3
“Treatment with HDAC1 inhibitors cause release of HDAC1 protein from the Sp1 (Promoter-specific RNA Polymerase II transcription factor), and promote p21 transcription and regulation of tumor growth [14].”
Bilinovich, S. M., Chhetri, S. B., Mitchell, J. T., Leighton, G. O., Jdanov, V., Zieba, J. K., Cook, T. W., Engel, K. L., Vaughan, R. M., Bhatti, H., et al. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00749.2024 · Cited by 3
Kim, B., Kantha, C., Kang, W., Jayaprakash, N., & Chung, H. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118192 · Cited by 3
Crosstalk between NLRP3 Signaling and Histone Deacetylases in Inflammasome-Driven Diseases
Tan, K., Rodríguez-Fernández, M. M., Keuler, T., Hansen, F. K., Gütschow, M., Weindl, G., & Marco, J. L. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02657 · Cited by 6
Li, Y., Liu, S. Q., Chu, C., & Yang, J. (2026) · iScience · doi:10.1016/j.isci.2026.115217 · Cited by 5
“19,20 Notably, distinct HDAC subtypes exhibit differential substrate specificity toward β -hydroxybutyrylation.”
Advantages of PROTACs in achieving selective degradation of homologous protein families
Yang, L., Mao, X., Zhang, J., Shu, J., Huang, W., Dong, X., Chen, Y., & Wu, M. (2026) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.22.49 · Cited by 3
Impact of epigenetic modifiers on the immune system
Bhat, S. A., Sureshbabu, S. K., Philip, C. S., & Chiplunkar, S. V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817964-2.00014-9 · Cited by 4
Akkermansia muciniphila – obiecujący kandydat na probiotyk nowej generacji
Markowska, E., & Kiersztan, A. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2021-0036 · Cited by 4
Yuan, Y., Li, D., Hu, X., Li, Y., Yi, W., Li, P., Zhao, Y., Li, Z., Yu, A., Jian, C., et al. (2022) · Medical Oncology · doi:10.1007/s12032-022-01684-1 · Cited by 3
“Evidences validated the synergistic anti-tumor activities of HDACis in combination with conventional therapies in cancers, by virtue of ameliorating sensitivity to the standard-dose therapy compared to monotherapy, accompanied by synergistic antitumor activities [12, 13].”
BackgroundAskari, M., Shahabi, M., Kojabad, A. A., & Zarif, M. N. (2023) · Cytotechnology · doi:10.1007/s10616-022-00564-w · Cited by 3
“Further, NAM inhibits nicotinamide adenine dinucleotide (NAD +) dependent histone deacetylase such as SIRT1, a sirtuin family member (Hwang and Song 2017).”
BackgroundInfluentialSynergizing GA-XGBoost and QSAR modeling: Breaking down activity cliffs in HDAC1 inhibitors
Jawarkar, R. D., Mali, S. N., Deshmukh, P. K., Ingle, R. G., Al‐Hussain, S. A., Al‐Mutairi, A. A., & Zaki, M. E. A. (2024) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2024.108915 · Cited by 4
Shen, C., Wang, S., Lee, K.-D., Liu, H.-T., Huang, S., Wu, J., & Liu, Y. (2025) · Heliyon · doi:10.1016/j.heliyon.2024.e41589 · Cited by 3
Lee, H., Kim, H., Min, J., Lee, E. H., Choi, D. K., Choi, J., Seo, Y., Lee, S., Im, C. Y., Bae, G. H., et al. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70057 · Cited by 3
“Sirtuins, including SIRT1 and SIRT2, are involved in various cellular processes such as gene expression control, DNA repair, and aging-related processes [14, 26–28].”
HDAC/σ1R Dual-Ligand as a Targeted Melanoma Therapeutic
Leotta, C. G., Barbaraci, C., Fiorito, J., Coco, A., di Giacomo, V., Amata, E., Marrazzo, A., & Pitari, G. M. (2025) · Pharmaceuticals · doi:10.3390/ph18020179 · Cited by 3
Fathy, A., Allam, A., ElHady, A. K., El‐Gamil, D. S., Lin, K.-C., Chang, Y.-H., Lee, Y., Hilscher, S., Schutkowski, M., Ibrahim, H. S., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00086f · Cited by 3
Liu, B., Wang, M., Pu, N., Wang, J., Fan, W., Qu, C., Wu, H., Song, Z., & Tao, Y. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102788 · Cited by 3
Metadata
- Authors
- Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J.
- Affiliations
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, Prague 5 CZ-150 06, Czech Republic
- Charles University (CZ)
- Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030/8, Prague 2 CZ-128 43, Czech Republic
- ORCID
- Stiborova, Marie
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-07-01
- Volume
- 18
- Issue
- 7
- Pages
- 1414
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5535906
- OpenAlex
- W2724336500
- Cited by
- 1,206
- References
- 184
- Citations by year
- 2026: 64 · 2025: 107 · 2024: 107 · 2023: 140 · 2022: 164 · 2021: 195 · 2020: 170 · 2019: 164 · 2018: 85 · 2017: 9
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministerstvo Zdravotnictví Ceské Republiky (00064203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, epigenetic regulation, histone acetylation, histone acetyltransferase, differentiation therapy, angiogenesis, immune response, vorinostat, romidepsin, belinostat, panobinostat, T-cell lymphoma, multiple myeloma, epigenetic therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, Angiogenesis Inhibitors, Epigenesis, Genetic, Histone Deacetylase Inhibitors, Immunomodulation, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
